Short course hormone therapy for prostate cancer
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial tests a short course of hormone therapy (androgen deprivation therapy) for men with a certain type of prostate cancer that is considered high-risk. The goal is to see if a shorter treatment period can still control the cancer while reducing side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be a man aged 18 or older.
- You must have been diagnosed with prostate cancer that meets certain high-risk features, such as a gleason score of 8 to 10, or a PSA level above 20 but not more than 40.
- You must have a low or intermediate risk score on a special test called the ARTERA AI test.
- You must not have cancer that has spread to your lymph nodes or other parts of the body.
- You must not have had more than 3 months of prior hormone therapy for prostate cancer.
- You must not have had previous treatments for prostate cancer, like surgery or chemotherapy, except for certain minor procedures.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a combination of short-term hormone therapy (relugolix) and focused radiation (SBRT) can treat a certain type of prostate cancer that is considered favorable but has a higher genetic risk. It aims to find a less intense treatment that still works well.
This trial studies a more sped-up radiation schedule for men with certain local prostate cancers, given together with hormone therapy. It aims to keep cancer control while possibly reducing treatment time and making care easier.
This study tests whether a shorter course of a newer hormone pill (apalutamide or enzalutamide) works well for men whose prostate cancer has spread to just a few spots and who recently started standard hormone therapy. It may allow you to take medication for less time while still controlling the cancer.
This trial tests a shorter course of radiation therapy (hypofractionated radiotherapy) for men who have already had their prostate removed and still have signs of cancer (like rising PSA). The goal is to see if this can help prevent the cancer from coming back.
This trial tests a shorter course of radiation therapy with an extra 'boost' to the most aggressive part of the tumor, combined with hormone therapy, for men with high-risk or locally advanced prostate cancer that has not spread outside the pelvis.
This trial compares two lengths of hormone treatment (androgen deprivation therapy) given around “salvage” radiation after prostate surgery for rising PSA. It aims to see which schedule works best to control prostate cancer while keeping side effects manageable.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.